Trump Reschedules Cannabis, FDA Fast-Tracks Psychedelics in Historic Week

Editor's Brief

Sunday, April 26, 2026 — and the federal government's relationship with controlled substances is shifting faster than a diesel autoflower in week three. Trump's rescheduling of cannabis to Schedule III is dominating headlines, drawing praise from Democratic governors and skepticism from advocates who want clemency, not just classification changes.

Meanwhile, the FDA is moving at rare speed to fast-track psychedelic drug trials following a presidential executive order — a development with real implications for the broader landscape of plant medicine. On the state level, Missouri is cracking down on intoxicating hemp products while Virginia's cannabis sales framework remains in legislative limbo.

For growers and consumers, the message is mixed: federal winds are shifting, but the storm isn't over yet.

Top Story

Cannabis Hits Schedule III — But Don't Celebrate Just Yet

The Trump administration's move to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act marks the most significant federal shift in marijuana policy in decades. Pennsylvania Governor Josh Shapiro called it an "important step," noting that "practically every one of our neighbors has legalized marijuana and is benefiting from hundreds of millions of dollars in economic activity and revenue."

The rescheduling itself does not legalize cannabis — not for personal use, not for home cultivation, and not for interstate commerce. What it does do is reduce federal penalties, open the door for broader medical research, and ease the crippling 280E tax burden that has strangled cannabis businesses for years. For the industry, that last point alone is worth billions.

But advocacy organizations are drawing a hard line. Groups including NORML, MPP, and the Last Prisoner Project are calling on Trump to pair rescheduling with executive clemency for people still incarcerated on cannabis charges. As High Times reports, rescheduling doesn't free anyone currently behind bars — and tens of thousands of Americans remain imprisoned for offenses that are now treated differently under federal law.

Watch for North Carolina and Pennsylvania to accelerate their own legalization discussions in the wake of this move. As AP News asks: will rescheduling have any real impact on criminal justice reform? The answer, so far, is a cautious no — unless clemency follows.

Policy & Legalization

Pennsylvania Eyes Full Legalization

Governor Shapiro is using the federal rescheduling as political momentum to push for adult-use legalization in Pennsylvania. The state is increasingly surrounded by legal markets in New York, New Jersey, and Maryland. Key takeaway: Pennsylvania legalization could unlock one of the largest remaining East Coast markets.

Missouri Bans Intoxicating Hemp THC Products

Missouri Governor Mike Kehoe signed legislation this week removing all intoxicating hemp-derived THC products from retail shelves, citing child safety concerns. The move aligns Missouri with anticipated federal recriminalization of hemp-derived THC. Key takeaway: The hemp gray market is shrinking fast — state by state, the loophole is closing.

White House Weighs In on Hemp Regulation

White House officials are actively providing feedback on pending federal hemp legislation, including a proposal to accelerate enforcement of hemp-derived THC bans. A separate GOP-backed amendment would fast-track that crackdown significantly. Key takeaway: If you're in the hemp cannabinoid space, the regulatory clock is ticking louder than ever.

Business & Markets

Virginia's Cannabis Sales Bill Sent Back to Governor

The Virginia General Assembly rejected Governor Abigail Spanberger's proposed amendments to the state's adult-use cannabis sales framework, sending the bill back to her desk unchanged. The standoff leaves Virginia's retail cannabis future uncertain heading into summer. Operators in the state are watching this one closely — the longer it drags, the longer the gray market thrives.

Texas Smokable Hemp Gets a Brief Reprieve

Texas hemp retailers selling flower and pre-rolls got a short-term lifeline as court delays push the next trial date to at least April 28 in a lawsuit challenging the state's smokable hemp ban. The Texas Hemp Business Council filed suit earlier this month. This is a temporary exhale — not a victory — for Texas hemp businesses.

Canadian Cannabis Sales Hold Steady in February

Statistics Canada reported February cannabis retail sales of C$440.5 million, down 7.9% from January but up 2.0% on a per-day basis — a nuance explained by February's shorter month. The Canadian market continues its slow, steady maturation. Year-over-year trends remain positive, a reassuring signal for international market watchers.

Science & Cultivation

FDA Fast-Tracks Psychedelic Drug Trials

Following Trump's executive order on psychedelics, the FDA granted expedited review status to three psychedelic drug trials — covering compounds including psilocybin, LSD analogs, and ibogaine. Federal health officials say this will "accelerate" therapeutic access for patients with serious mental health conditions.

This matters for the cannabis world because it signals a broader federal willingness to revisit the science of scheduled substances. The infrastructure being built for psychedelic research could — and likely will — benefit cannabis medical research timelines as well. Rescheduling to Schedule III means cannabis research no longer faces the same near-impossible DEA supply restrictions it once did.

The Case for Medical Cannabis Grows Stronger

The Fresh Toast highlights the growing body of evidence supporting medical marijuana's role in modern healthcare, from chronic pain management to neurological applications. Patient demand is reshaping clinical conversations faster than formal research pipelines can keep up. For home growers producing personal medicine, this cultural and scientific validation matters.

Crime & Enforcement

Pacific Grove Traffic Stop Yields Drug Arrest

A routine traffic stop in Pacific Grove, California led to the arrest of a driver found in possession of both methamphetamine and marijuana, according to SFGATE. While cannabis alone wouldn't typically result in arrest in California, the combination of substances escalated the stop. A reminder that driving with any controlled substance remains a serious enforcement priority — even in legal states.

Culture & Community

Kal Penn Is Still Getting Offered Weed Everywhere

In a delightful High Times interview, Harold & Kumar star Kal Penn talks about finally meeting Cheech Marin, the strain deal he wishes he'd gotten years ago, and why he remains an accidental cannabis ambassador to this day. It's the kind of warm, human story this industry needs more of. Read it — you'll smile.

Who Decides What Cannabis Conversations Are Allowed?

High Times explores the controversy around Fat Nugs Magazine's "Kids and Cannabis" issue, which was refused by a partner dispensary. The story raises sharp questions about self-censorship within the cannabis industry and who controls the boundaries of acceptable discourse. It's a tension between normalization and caution — and there are no easy answers.

What This Means for Growers

• Schedule III rescheduling opens the research door: Expect more credible, federally-supported cannabis science in the next 12–24 months. Better research means better understanding of cannabinoid profiles, terpene interactions, and cultivation best practices backed by real data.
• Home growers remain in a gray zone: Rescheduling does not decriminalize personal cultivation at the federal level. Know your state laws — enforcement priorities may shift, but federal exposure hasn't disappeared.
• Hemp seed and clone buyers should move carefully: With Missouri banning intoxicating hemp THC products and federal legislation tightening, high-THC hemp genetics are under increasing scrutiny. Compliance documentation for your plants matters now more than ever.
• The psychedelic research boom could spill over: Federal infrastructure being built for psilocybin and ibogaine research may accelerate acceptance of cannabis-based medicine — particularly for PTSD, anxiety, and chronic pain applications that growers producing personal medicine care deeply about.
• Watch Pennsylvania and North Carolina: If either state moves toward adult-use legalization, new regulated seed and clone markets will emerge — along with legal home grow provisions that could matter directly to enthusiast cultivators in those regions.

Quick Links

Full source links are listed below this article.